CLX vs KVUE
Clorox and Kenvue, both Consumer Defensive
Kenvue is the larger company at $35B against $12B. On trailing earnings CLX is the cheaper of the two at a P/E of 16.9 against 22.1, a gap that is only a bargain if the two are growing at similar rates. Over the past year KVUE returned -6.2% against -13% for CLX. Ryufin's sector-relative Smart Score puts KVUE ahead, 8/10 against 6/10.
| Figure | CLX | KVUE |
|---|---|---|
| Last close | $104 | $19.22 |
| Market cap | $12B | $35B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 16.9 | 22.1 |
| Dividend yield | 4.7% | 4.3% |
| 1-year return | -13% | -6.2% |
| 5-year return | -32% | n/a |
| Ryufin Smart Scoresector-relative, 1–10 | 6/10 | 8/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Clorox
Revenue of $1.7B in Q3 2026, net income $187M. Its largest reported line is Health And Wellness, 38% of the disclosed total.
Kenvue
Revenue of $4.0B in Q2 2026, net income $456M. Its largest reported line is Self Care, 43% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.